peppersite
Peptide

ARA-290

ARA-290 (cibinetide) is a lab-made chain of 11 amino acids modelled on the helix-B region of erythropoietin, a hormone known for driving red blood cell production. It is studied for nerve and tissue protection in animal models and small human trials.

Researched for
Recovery

At a glance

Type
Peptide
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
4 mg per Peptide Protocol Wiki. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 4 mg, the figure Peptide Protocol Wiki reports for ARA-290. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for ARA-290 or for anything else, and nothing below has been checked against the study it came from.

4 mg
Frequency
Once daily28 days
Route
subcutaneous or intranasal or oral
Reported by
Peptide Protocol Wiki
Not yet audited

We have not published an audit on ARA-290. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

ARA-290 is designed to switch on a protective signal in stressed or injured tissue without raising red blood cell production the way erythropoietin does. In a rat nerve-injury model it reduced pain-like responses to touch and cold, and small human trials reported changes in corneal nerve fibre measures. Researchers link this to the innate repair receptor, a complex of the erythropoietin receptor and the beta-common receptor (CD131). The source cautions that receptor activity and animal results can fail to turn into meaningful benefit in people.

Reported side effects

Seen in studies: a 2012 double-blind pilot study of 22 patients, given 2 mg by vein three times weekly for 4 weeks, reported no safety concerns. A 12-week open-label pilot of daily 4 mg under the skin in diabetic macular edema is described as informing feasibility and safety monitoring. The source names no specific adverse events or rates.

Not ruled out: safety data are limited by small studies, short follow-up and investigational use. Questions about drug interactions, pregnancy, breastfeeding, blood clots (thrombosis), cancer and immune disease remain unanswered.

Who should avoid it

People who are pregnant or breastfeeding: the source says these questions remain unanswered because safety data are limited.

People with a history of blood clots or cancer: approved erythropoiesis-stimulating drugs carry major warnings on thrombosis, cardiovascular events and tumour progression. ARA-290 was engineered to avoid that activity, but the source says this does not prove it safe for all users.

People with immune disease: unanswered, because the safety data come from small, short studies.

People on other medicines: drug interactions remain an open question for the same reason.

What gets monitored

The page mentions the following assessments used in clinical trials that could inform monitoring: corneal nerve fiber area and corneal nerve fiber density (via corneal confocal microscopy), intraepidermal nerve fiber markers, Small Fiber Neuropathy Screening List scores, Brief Pain Inventory, PainDetect scores, fatigue scales, quality-of-life measures, HbA1c, and lipid measures. These are described as study endpoints, not as a formal monitoring protocol. (reported by Peptide Dosages)

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things